These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 24643243)
21. Structural and evolutionary analysis of Leishmania Alba proteins. da Costa KS; Galúcio JMP; Leonardo ES; Cardoso G; Leal É; Conde G; Lameira J Mol Biochem Parasitol; 2017 Oct; 217():23-31. PubMed ID: 28847609 [TBL] [Abstract][Full Text] [Related]
22. Biochemical and genetic tests for inhibitors of Leishmania pteridine pathways. Hardy LW; Matthews W; Nare B; Beverley SM Exp Parasitol; 1997 Nov; 87(3):157-69. PubMed ID: 9371081 [TBL] [Abstract][Full Text] [Related]
23. Foreword. Trypanosomatid disease drug discovery and target identification. N Setzer W Future Med Chem; 2013 Oct; 5(15):1703-4. PubMed ID: 24144406 [No Abstract] [Full Text] [Related]
24. Interactions of antiparasitic alkaloids with Leishmania protein targets: a molecular docking analysis. Ogungbe IV; Ng JD; Setzer WN Future Med Chem; 2013 Oct; 5(15):1777-99. PubMed ID: 24144413 [TBL] [Abstract][Full Text] [Related]
25. Joining forces: first application of a rapamycin-induced dimerizable Cre system for conditional null mutant analysis in Leishmania. Späth GF; Clos J Mol Microbiol; 2016 Jun; 100(6):923-7. PubMed ID: 26991431 [TBL] [Abstract][Full Text] [Related]
26. In silico work flow for scaffold hopping in Leishmania. Waugh B; Ghosh A; Bhattacharyya D; Ghoshal N; Banerjee R BMC Res Notes; 2014 Nov; 7():802. PubMed ID: 25399834 [TBL] [Abstract][Full Text] [Related]
27. Homology modeling of T. cruzi and L. major NADH-dependent fumarate reductases: ligand docking, molecular dynamics validation, and insights on their binding modes. Merlino A; Vieites M; Gambino D; Coitiño EL J Mol Graph Model; 2014 Mar; 48():47-59. PubMed ID: 24370672 [TBL] [Abstract][Full Text] [Related]
28. (Post-) Genomic approaches to tackle drug resistance in Leishmania. Berg M; Mannaert A; Vanaerschot M; Van Der Auwera G; Dujardin JC Parasitology; 2013 Oct; 140(12):1492-505. PubMed ID: 23480865 [TBL] [Abstract][Full Text] [Related]
29. Advances and perspectives in Leishmania cell based drug-screening procedures. Sereno D; Cordeiro da Silva A; Mathieu-Daude F; Ouaissi A Parasitol Int; 2007 Mar; 56(1):3-7. PubMed ID: 17079188 [TBL] [Abstract][Full Text] [Related]
31. The role of reduced pterins in resistance to reactive oxygen and nitrogen intermediates in the protozoan parasite Leishmania. Moreira W; Leblanc E; Ouellette M Free Radic Biol Med; 2009 Feb; 46(3):367-75. PubMed ID: 19022374 [TBL] [Abstract][Full Text] [Related]
33. Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery. Chandra S; Ruhela D; Deb A; Vishwakarma RA Expert Opin Ther Targets; 2010 Jul; 14(7):739-57. PubMed ID: 20536412 [TBL] [Abstract][Full Text] [Related]
34. An in silico approach in identification of drug targets in Leishmania: A subtractive genomic and metabolic simulation analysis. Meshram RJ; Goundge MB; Kolte BS; Gacche RN Parasitol Int; 2019 Apr; 69():59-70. PubMed ID: 30503238 [TBL] [Abstract][Full Text] [Related]
35. Genetics. Leishmania exploit sex. Miles MA; Yeo M; Mauricio IL Science; 2009 Apr; 324(5924):187-9. PubMed ID: 19359570 [No Abstract] [Full Text] [Related]